Bio News
China will officially introduce “new approach methodologies (NAMs)” using organoids and AI into preclinical drug evaluation. The initiative aims to standardize and commercialize the technologies, with details to be disclosed Sept. 3 at the sixth Organoid Conference. More than 500 companies have participated in the conference in the past.
Biobook Team
biobookmedia@biobook.co.krMinistry of Trade, Industry and Energy and Ministry of Food and Drug Safety Sign Agreement on AI Transformation and Global Competitiveness in Biotech
Paragon Spin-Off Velaris Goes Public Through Reverse Merger With Alaunos
Syndax halts development of Niktimvo for pulmonary fibrosis; shares plunge 17%
BioNTech’s mRNA Cancer Vaccine Misses Primary Endpoint for Progression-Free Survival in Phase 3 Trial
Roche Signs $1.6 Billion Deal With China’s Rona for ALK7 Obesity Drug
Formycon and Zydus’ Keytruda Biosimilar Is First to Be Accepted for FDA Review
